TMCnet News
SynteractHCR Presenting and Exhibiting at DIA 2016 Annual Meeting in PhiladelphiaSynteractHCR, a full-service, international contract research organization (CRO), will participate in the Drug Information Association (DIA) 2016 52nd Annual Meeting, which runs from June 26-30 at the Philadelphia Convention Center. The company will exhibit in booth #917. In addition, Dr. Stephan de la Motte, the company's chief medical advisor, will participate in a panel discussion on "Rare Disease Clinical Trials: Coping with Unique Challenges" on Monday, June 27 at 8:30 a.m. As the complexity of clinical trials continues to ramp up, SynteractHCR's overarching focus for DIA 2016 is on providing "expertise to guide your most complex trials to confident results." SynteractHCR's experts are prepared to discuss how the company's consultative approach and full service offering address the needs of innovative drug and device developers regarding:
During Dr. de la Motte's presentation, panelists will address:
SynteractHCR will have its own team of recruitment professionals available to discuss global career opportunities within the company, particularly in the areas of clinical operations, biostatistics and safety. Sponsors interested in setting a private appointment, please contact Executive Director of Business Development Kim Martinez at 760-529-3440 or [email protected]. SynteractHCR will post live updates from DIA on Twitter (News - Alert) @SynteractHCR. Visit global-cro.synteracthcr.com/dia2016 for more information and to sign up to receive informative handouts. About SynteractHCR SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its "Shared Work - Shared Vision" philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow's treatments to patients. View source version on businesswire.com: http://www.businesswire.com/news/home/20160614006090/en/ |